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CXCR7 antagonism prevents axonal injury during
experimental autoimmune encephalomyelitis as
revealed by in vivo axial diffusivity
Lillian Cruz-Orengo1, Ying-Jr Chen2, Joong Hee Kim2, Denise Dorsey1, Sheng-Kwei Song2 and Robyn S Klein1,3,4*
Abstract
Background: Multiple Sclerosis (MS) is characterized by the pathological trafficking of leukocytes into the central
nervous system (CNS). Using the murine MS model, experimental autoimmune encephalomyelitis (EAE), we
previously demonstrated that antagonism of the chemokine receptor CXCR7 blocks endothelial cell sequestration
of CXCL12, thereby enhancing the abluminal localization of CXCR4-expressing leukocytes. CXCR7 antagonism led to
decreased parenchymal entry of leukocytes and amelioration of ongoing disease during EAE. Of note, animals that
received high doses of CXCR7 antagonist recovered to baseline function, as assessed by standard clinical scoring.
Because functional recovery reflects axonal integrity, we utilized diffusion tensor imaging (DTI) to evaluate axonal
injury in CXCR7 antagonist- versus vehicle-treated mice after recovery from EAE.
Methods: C57BL6/J mice underwent adoptive transfer of MOG-reactive Th1 cells and were treated daily with either
CXCR7 antagonist or vehicle for 28 days; and then evaluated by DTI to assess for axonal injury. After imaging,
spinal cords underwent histological analysis of myelin and oligodendrocytes via staining with luxol fast blue (LFB),
and immunofluorescence for myelin basic protein (MBP) and glutathione S-transferase-π (GST-π). Detection of non-
phosphorylated neurofilament H (NH-F) was also performed to detect injured axons. Statistical analysis for EAE
scores, DTI parameters and non-phosphorylated NH-F immunofluorescence were done by ANOVA followed by
Bonferroni post-hoc test. For all statistical analysis a p < 0.05 was considered significant.
Results: In vivo DTI maps of spinal cord ventrolateral white matter (VLWM) axial diffusivities of naïve and CXCR7
antagonist-treated mice were indistinguishable, while vehicle-treated animals exhibited decreased axial diffusivities.
Quantitative differences in injured axons, as assessed via detection of non-phosphorylated NH-F, were consistent
with axial diffusivity measurements. Overall, qualitative myelin content and presence of oligodendrocytes were
similar in all treatment groups, as expected by their radial diffusivity values. Quantitative assessment of persistent
inflammatory infiltrates revealed significant decreases within the parenchyma of CXCR7 antagonist-treated mice
versus controls.
Conclusions: These data suggest that CXCR7 antagonism not only prevents persistent inflammation but also
preserves axonal integrity. Thus, targeting CXCR7 modifies both disease severity and recovery during EAE,
suggesting a role for this molecule in both phases of disease.
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Background
Axonal injury is a critical factor in the progression of
neurologic deficits in patients with multiple sclerosis
(MS) [1]. Axonal degeneration may occur as a result of
oligodendrocyte death and demyelination due to altera-
tions in trophic support and/or impaired mitochondrial
bioenergetics [2-7]. Recent studies also indicate that infil-
trating leukocytes may directly induce axonal damage
that is reversible and occurs in the absence of demyelina-
tion [8]. Disease modifying therapies that limit the forma-
tion and extent of inflammatory lesions may therefore
provide the best approach for preventing disability. In
addition, imaging modalities that identify injured axons
are critical for monitoring patient responses to these
agents.
Recent data examining the dynamic expression of the
chemokine CXCL12 at the blood-brain barrier (BBB)
indicate that activity of CXCR7, a CXCL12 receptor that
sequesters the chemokine intracellularly [9-11], is criti-
cal for the entry of infiltrating leukocytes in mice with
experimental autoimmune encephalomyelitis (EAE), a
murine model for MS [12]. CXCL12 expression along
abluminal surfaces of the CNS vasculature normally
localizes infiltrating CXCR4-expressing leukocytes to
perivascular spaces, thereby restricting their entry into
the CNS [13,14]. Loss of abluminal CXCL12, which is
specific to MS [15], occurs via cytokine-mediated, up-
regulation of CXCR7 by CNS endothelial cells [12].
Administration of a specific CXCR7 antagonist led to
retention of abluminal CXCL12 expression at the BBB
microvasculature, preventing the pathological entry of
immune cells into the CNS parenchyma. Animals that
received CXCR7 antagonist exhibited a dose-dependent
decrease in peak disease severity and amelioration of
ongoing disease [12]. In all circumstances, high doses of
CXCR7 antagonist also led to complete clinical recovery
while vehicle or untreated animals exhibited chronic
deficits. The lack of detectable clinical deficits in ani-
mals with limited parenchymal entry of immune cells
supports the notion that inflammation leads to reversi-
ble axonal injury, which can be ameliorated by targeting
CXCR7.
Quantitative analysis of white matter injury in models
of MS has been fraught with difficulties due to uneven
qualities of the pathology. Diffusion Tensor Imaging
(DTI) has emerged as a powerful and sensitive tool to
analyze white matter disease. Specifically, DTI has been
utilized to assess axonal damage and demyelination in
vivo in both MS and in animal models such as EAE
[16-22]. DTI measures the directional diffusivities of
water molecules, which reflect the microstructural orga-
nization in biological specimens [23,24]. Radial diffusiv-
ity, the diffusion of water perpendicular to the axonal
fiber, is associated with myelin integrity and therefore
increases during demyelination [22,25]. Axial diffusivity,
which reflects microscopic water movement parallel to
the axonal fiber, is decreased with loss of axonal integrity
[16,17,20,22]. DTI is therefore suitable for the quantita-
tive assessment of myelin versus axonal injury in preclini-
cal studies evaluating novel targets for the treatment
of MS.
In the current study, we utilized in vivo DTI to examine
axonal and myelin injury in vehicle- versus CXCR7
antagonist-treated mice after recovery from EAE. We
observed that axial diffusivity within the ventrolateral
white matter (VLWM) of mice treated with high doses of
CXCR7 antagonist was comparable to naïve mice
whereas untreated or vehicle-treated animals showed sig-
nificant axial diffusivity reduction, suggesting axonal
damage. However, we did not observe changes in radial
diffusivity between treatment groups, suggesting that
CXCR7 antagonism did not impact on levels of myelin
during recovery. These results validate the relevance of
CXCR7 as a disease modifying molecule not only during
the effector phase of EAE, by preventing intraparenchy-
mal leukocyte migration, but also during the recovery
phase, by preserving axonal integrity. Moreover, the
results also support the use of DTI for assessing the in
vivo therapeutic efficacy of treatments for CNS autoim-
mune diseases.
Materials and methods
Animals and antibodies
C57BL/6 mice (Jackson Labs, Bar Harbor, ME) were
maintained in pathogen free conditions (Department of
Comparative Medicine, Washington University, St. Louis,
MO) and studies were performed in compliance with the
guidelines of the Washington University School of Medi-
cine Animal Studies Committee. Antibodies utilized
include rabbit anti-CD3 (Dako, Glostrup, Denmark), rat
anti-GFAP (Invitrogen, Carlsbad, CA), rabbit anti-GST-π
(Assays Designs-Enzo Life Sciences, Inc. Farmingdale,
NY), rat anti-MBP (Abcam, Cambridge, MA) and mouse
monoclonal SMI-32 (Covance, Emeryville, CA). IgG from
rabbit, rat (Invitrogen, Carlsbad, CA) and mouse (BD
Pharmigen, San Diego, CA) were used as isotype con-
trols. Secondary detection was done using goat anti-rat,
anti-rabbit and anti-mouse conjugated to Alexa-555 and
goat anti-rabbit, and anti-rat conjugated to Alexa-488
(Molecular Probes-Invitrogen, Carlsbad, CA).
Experimental autoimmune encephalomyelitis induction
Autoreactive Th1 cells directed to myelin oligodendro-
cyte glycoprotein peptide (MOGp) were generated as
previously described [12]. Briefly, naïve C57BL/6 mice
were immunized with 50 μg msMOGp35-55 (GenScript,
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Piscataway, NJ) and 50 μg Mycobacterium tuberculosis
H37Ra peptide emulsified in Freund’s adjuvant (both
from Difco Laboratories, Detroit, MI). After 14 days,
polarized Th1 cells were harvested from spleen using a
nylon wool column. MOG-reactive Th1 cells were resti-
mulated and expanded in culture according to standard
protocols prior to adoptive transfer to naïve recipients
[12]. 5 × 106 Th1 cells were incubated with 25 × 106 sti-
mulators-cells obtained from naïve splenocytes. Incuba-
tion proceeded in the presence of MOG, anti-IL-4, IL-2
(both generated in the lab) and IL-12 (BD Pharmigen,
San Diego, CA) in RPMI enriched media. Cells were
incubated at 37°C for 7 days. After separation with His-
topaque (Sigma Aldrich, Saint Louis, MO) 1 × 107 Th1
cells were restimulated with 5 × 107 stimulators-cells for
other 7 days as described above. Th1 cells underwent a
third stimulation of only 4 days in the presence of
MOG and IL-2. Following Histopaque separation cells
were resuspended in HBSS at 1 × 107 MOG-reactive
Th1 cells/300 ul per mouse ratio. Adoptive transfer of
10 × 106 MOG-reactive Th1 cells per mouse was done
retro-orbitally. Recipient mice were monitored for clini-
cal manifestations of EAE by following their body weight
and graded for disease with the following score system: 1,
tail weakness; 2, difficulty righting; 3, hind limb paralysis;
4, forelimb weakness; 5, moribund or dead.
In vivo administration of CCX771, a CXCR7 antagonist
Mice underwent daily subcutaneous injection of either
vehicle (10% Captisol) or CCX771 (ChemoCentryx,
Mountainview, CA) at doses of 5 or 10 mg/kg of body
weight beginning 12 hours after adoptive transfer (5 mice
per treatment group). A cohort of mice started with vehi-
cle and changed to CCX771 at a dose of 10 mg/kg of
body weight when achieved a score of 1. Dosing with
CXCR7 antagonist or vehicle and monitoring for clinical
progression continued for 28 days.
Diffusion Tensor Imaging (DTI) and analysis
Twenty five EAE mice and five naïve control littermates
underwent in vivo DTI with isoflurane/oxygen anesthesia
(5% induction and 1% maintenance) delivered by a custom
nose cone that also allowed respiratory-gated acquisition.
The mice were placed in a custom holder designed to
immobilize the spine and isolate respiratory motion. An
actively detuned radiofrequency transmit coil (6 cm inter-
nal diameter × 10 cm length) was used with a receiver coil
(16 mm internal diameter × 9 mm length) designed to fit
around the spine of the mouse. The entire preparation
was placed in an Oxford Instruments 200/330 magnet (4.7
T, 40 cm clear bore) equipped with a 20 cm inner-
diameter, actively shielded Magnex gradient coil (up to
60 G/cm, 280 μs rise time). Core temperature was main-
tained at 37°C with circulating warm water. The magnet,
gradient coil, and gradient power supply were interfaced
with a INOVA console (Varian NMR Systems, Palo Alto,
CA) controlled by a Sun Blade 1500 workstation (Sun
Microsystems, Santa Clara, CA).
Axial scout images of the spine were acquired for proper
localization of spinal cord level. Multiple transverse slices
covering spinal cord lumbar enlargement were obtained
using a Stejskal-Tanner [16,17,20,26] spin-echo diffusion
weighted sequence with the following acquisition para-
meters: TR ~1500 msec. (determined by the respiratory
rate of the mouse), TE of 37 msec., number of excitations
equals 2, slice thickness of 1 mm, spinal cord field of view
of 1 cm × 1 cm, data matrix of 128 × 128 (zero-filled to
256 × 256). Diffusion-sensitizing gradients were applied in
six orientations: (Gx, Gy, Gz) equal to (1, 1, 0), (1, 0, 1), (0,
1, 1), (-1, 1, 0), (0, -1, 1), and (1, 0, -1) with a gradient
strength of 9 G/cm, duration (δ) equal to 7 msec., and
separation (Δ) of 18 msec., to obtain b values of 0 and
0.750 s/mm2. Acquisition time was approximately one
hour for each spinal cord scanning session.
Using a weighted linear least square method, diffusion
tensors and DTI parameters were generated. In this
study, three DTI parameter maps were used, relative ani-
sotropy (RA), axial diffusivity (l||), and radial diffusivity
(l⊥) [27]. Regions of interest (ROIs) encompassing the
ventrolateral white matter (VLWM) were drawn manu-
ally on relative anisotropy (RA) maps projecting to axial
and radial diffusivity maps to assess axon and myelin
integrity respectively using ImageJ v1.37 software (devel-
oped at the U.S. National Institutes of Health and avail-
able on the Internet at http://rsbweb.nih.gov/ij/) [28-30].
Injured VLWM region was identified using the baseline
axial diffusivity threshold derived from the spinal cord of
naïve mice.
Histological and immunofluorescent analyses
Murine spinal cords were isolated for histological analysis
after imaging. Briefly, anesthetized animals were intracar-
dially perfused with PBS and fixed in 4% PFA followed by
overnight post-fixation in 4% PFA. Spinal cords were cryo-
protected in 30% sucrose prior to embedding in OCT
media for cryosectioning. For lumbar segment identifica-
tion luxol fast blue (LFB) was done following standard
procedure and visualized on the Zeiss Axioskop MOT
Fluorescent microscope and AxioVision software (both
from Carl Zeiss International, Jena, Germany).
Immunodetection of CD3+ lymphocytes within CNS
parenchyma was performed via co-labeling with GFAP.
Sections from lumbar segments of the spinal cord were
permeabilized and blocked in 0.1% Triton X-100 and 10%
goat serum for 60 minutes at room temperature. Sections
were incubated with primary antibody overnight at 4°C,
washed in PBS, incubated with secondary antibodies for
60 minutes at room temperature and counterstained with
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ToPro-3 (Invitrogen, Carlsbad, CA) to detect nuclei.
Immunostained sections were visualized on the Zeiss LSM
510 META Confocal Laser Scanning Microscope (Carl
Zeiss International, Jena, Germany). Measurement of
CD3+ pixels within the ROIs encompassing parenchyma
and meninges was done using the public domain NIH
Image program ImageJ.
To facilitate immunodetection of myelin basic protein
(MBP) and glutathione S-transferase-π (GST-π) frozen
sections from lumbar segments L2/L3 were submitted to
antigen retrieval in 0.1% trypsin, 0.1% CaCl in 0.05 M Tris
pH 7.4 at 37°C for 10 min. Then sections were permeabi-
lized and blocked in 0.1% Triton X-100 and 3% goat
serum for 60 minutes at room temperature. Primary anti-
body was incubated overnight at 4°C. Slides were washed
in 0.2% fish skin gelatin in PBS followed by incubation of
secondary antibodies for 60 minutes at room temperature.
After washing in 0.2% fish skin gelatin in PBS, slides were
nuclear stained with DAPI (Invitrogen, Carlsbad, CA) and
coverslip with Vectashield (Vector Laboratories, Inc.
Burlingame, CA) before being visualized on the Zeiss
Axioskop MOT Fluorescent microscope and AxioVision
software (both from Carl Zeiss International, Jena,
Germany).
For immunodetection of neurofiliament H frozen sec-
tions from lumbar segments L2/L3 were permeabilized
and blocked in 0.1% Triton X-100 and 10% goat serum
for 60 minutes at room temperature. Primary antibody
was incubated overnight at 4°C. Slides were washed in
PBS followed by incubation of secondary antibodies for
60 minutes at room temperature. After washing in PBS,
slides were nuclear stained with ToPro-3 (Invitrogen,
Carlsbad, CA) and coverslip with Shandon-Mount
(Thermo Fisher Scientific, Pittsburgh, PA) before being
visualized on the Zeiss LSM 510 META Confocal Laser
Scanning Microscope (Carl Zeiss International, Jena,
Germany). Measurement of SMI-32 positive signal area
within the ROIs encompassing the VLWM was done
using the public domain NIH Image program ImageJ.
Statistical analysis
All statistical analysis was done using Prism 5.0 (GraphPad
Software, Inc. La Jolla, CA). In vivo experiments for clini-
cal scoring and DTI imaging were performed with n = 5
animals per treatment group, and 3 mice per group were
further included in the histological studies. Data obtained
from clinical severity scores and SMI-32 staining was ana-
lyzed via Two-way ANOVA. Highest severity score by dis-
ease phase and RA, l⊥, l|| map histograms were analyzed
by one-way ANOVA. All analyses were followed by Bon-
ferroni post-hoc test. Correlation analysis was done
between l|| and area-under-curve (AUC) of the clinical
score. For all statistical analysis a p < 0.05 was considered
significant.
Results
CXCR7 antagonism promotes complete clinical recovery
during EAE
We recently demonstrated that CXCR7 antagonism ame-
liorates EAE induced by adoptive transfer of encephalito-
genic Th1 cells by decreasing both leukocyte entry into the
CNS parenchyma and demyelination [12]. Because both
loss of myelin and interactions between immune and neu-
ronal cells lead to axonal damage [31,32], we wondered
whether CXCR7 antagonism might affect the extent of
recovery. Mice underwent adoptive transfer of MOG-reac-
tive Th1 cells and were then administered daily injections
of saline, vehicle, 5 or 10 mg/kg of CCX771, a specific
antagonist of CXCR7 [12], and monitored for disease pro-
gression for a period of 28 days. In order to examine
whether limiting inflammatory infiltrates during ongoing
disease impacts on recovery, half of the vehicle-treated
mice began administration of CCX771 when they attained
a clinical score of 1. Consistent with our previous report
[12], CXCR7 antagonism led to a dose dependent decrease
in the peak severity of EAE even in mice with established
disease (Figure 1A). Evaluation of disease severity during
the recovery phase, 21 to 28 days post-transfer (blue
bracket in Figure 1A), revealed that CCX771-treated mice
exhibited a dose-dependent increase in recovery with signif-
icantly lower clinical severity scores than vehicle- or saline-
treated control groups (Tables 1 and 2 and Figure 1B). All
animals from both groups exhibited a highest severity score
of 2 during the recovery phase, 21 to 28 days post-transfer
(Figure 1B, recovery phase for vehicle and saline SEM = 0).
Of interest, animals treated with CCX771 that attained a
clinical score of 1 exhibited the same mean severity score
upon recovery phase, 21 to 28 days post-transfer (blue
bracket in Figure 1A), as those that began treatment at the
time of adoptive transfer, despite a significant difference in
their peak clinical disease severities during effector phase, 7
to 21 days post-transfer (red bracket in Figure 1A). (Figure
1A Two-way ANOVA interaction: F = 2.20, DFn = 108,
DFd = 560, P < 0.0001; antagonist treatment: F = 93.85,
DFn = 4, DFd = 560, P < 0.0001; day post-adoptive transfer:
F = 59.06, DFn = 27, DFd = 560, P < 0.0001; Figure 1B
Two-way ANOVA interaction: F = 1.71, P = 0.1659; disease
phase: F = 164.57, P < 0.0001; treatment: F = 22.21, P <
0.0001 and Table 1: One-way ANOVA effector phase: F =
8.250, P > 0.0004; Table 2: One-way ANOVA recovery
phase: F = 18.45, P < 0.0001). These data suggest that
CXCR7 antagonism not only modifies disease severity dur-
ing EAE but enhances overall recovery regardless of initial
impairments, as accessed via clinical scoring.
DTI reveals treatment efficacy of CXCR7 antagonist on
EAE mice
In vivo DTI was performed to assess microstructural
changes within multiple transverse slices of the lumbar
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enlargement of mouse spinal cords (Figure 2A) in
CCX771-, vehicle- or saline-treated mice after recovery
from peak EAE, plus age-matched naïve control mice.
Relative anisotropy (RA) maps were generated within
the manually defined regions of interest (ROIs) of
VLWM (Figure 2B). Axon and myelin injury in VLWM,
most severe in the control groups, was apparent in EAE
mice as evidenced by the intensity changes in radial and
axial diffusivity maps (Figure 2B). Statistical analysis of
changes in radial diffusivity failed to show significant
differences in the VLWM among study groups, suggest-
ing no differences in myelin integrity (Figure 2C, One-
way ANOVA F = 1.696, P = 0.1740). In contrast, analy-
sis of changes in VLWM axial diffusivity detected
Figure 1 CXCR7 antagonism ameliorates the clinical severity of EAE. Dose response effects of the CXCR7 antagonist, CCX771, were
evaluated during induction of and after treatment of ongoing adoptive transfer EAE. (A) Animals were grouped into those receiving daily
treatment with saline (yellow), vehicle (red) or CCX771 at 5 mg/kg (green) or 10 mg/kg (blue) beginning at the time of adoptive transfer or
when animals reached a score of 1 (purple). Results are expressed as mean clinical score ± SEM, n = 5. Two-way ANOVA for all treatment groups
showed a strong interaction of treatment and days post-adoptive transfer with disease progression: interaction: F = 2.201, P < 0.0001; antagonist
treatment: F = 93.85, P < 0.0001; days post-adoptive transfer: F = 59.06, P < 0.0001. (B) Comparison between the mean highest severity scores of
effector phase (red bracket on A) and recovery phase (blue bracket on A). Results are expressed as mean highest severity score ± SEM. Two-way
ANOVA P values summary: interaction: F = 1.71, P = 0.1659; disease phase: F = 164.57, P < 0.0001; treatment: F = 22.21, P < 0.0001).
Table 1 One-way ANOVA for effector phase.
saline vehicle 5 mg vehicle to 10 mg 10 mg
saline – ns * ns **
vehicle ns – * ns **
5 mg * * – ns ns
vehicle to 10 mg ns ns ns – ns
10 mg ** ** ns ns –
Summary of p values comparing the highest severity scores among treatment
groups. ns = non-significant, * = p < 0.05, ** p < 0.01, P = 0.0004, F = 8.250,
R2 = 0.6226.
Table 2 One-way ANOVA for recovery phase.
saline vehicle 5 mg vehicle to 10 mg 10 mg
saline – ns ns *** ***
vehicle ns – ns *** ***
5 mg ns ns – * *
vehicle to 10 mg *** *** * – ns
10 mg *** *** * ns –
Summary of p values comparing the highest severity scores among treatment
groups. ns = non-significant,* = p < 0.05, *** p < 0.001, P < 0.0001, F = 18.45,
R2 = 0.7868.
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significant decreases in groups of mice that received low
dose CCX771 (5 mg/kg), vehicle or saline versus those
that received high dose (10 mg/kg) and naïve mice
(Figure 2D). Axial diffusivity of 10 mg/kg CCX771-trea-
ted mice resembled the values of the naïve group, while
5 mg/kg CCX771-treated mice resembled those
obtained from control groups (Figure 2D, One-way
ANOVA F = 3.232, P = 0.0227). Lastly, RA of VLWM
showed no difference between vehicle- or saline-treated
mice and CCX771-treated mice (Figure 2E, One-way
ANOVA F = 5.272, P = 0.0021).
The extent of axonal preservation was assessed
according to the axial diffusivity distribution [16] from
the naïve spinal cords (Figure 3A) to distinguish the
injured from the normal appearing VLWM (Figure 3B).
No differences in the extent of injured VLWM were
detected between 10 mg/kg CCX771-treated and naïve
mice while 5 mg/kg CCX771-, vehicle-, and saline-trea-
ted mice exhibited gradations of injury within the
VLWM (Figure 3C).
We next inquired if changes in axial diffusivity after
CCX771 treatment correlated with disease recovery. To
answer this question we evaluated the mean clinical
score only during the recovery phase, 21 to 28 day post-
adoptive transfer, as a function of axial diffusivity VLWM
and injured VLWM. Both analyses showed a statistically
significant linear correlation of clinical score during the
recovery phase with axial diffusivity (Figure 4A, R2 =
0.5413, F = 33.04, DFn, DFd = 1.0, 28.0, P < 0.0001) and
injured VLWM (Figure 4B, R2 = 0.6520, F = 43.10, DFn,
DFd = 1.0, 23.0, P < 0.0001). In addition, linear correla-
tion between the temporal-cumulative clinical score and
injured VLWM at the time of DTI evaluation was signifi-
cant (Figure 4C, R2 = 0.7284, F = 61.69, DFn, DFd = 1.0,
Figure 2 DTI analysis shows changes in ventral white matter. At the end of clinical assessment mice from all treatment groups and naïve
littermates underwent in vivo DTI analysis. Spinal cord level was localized by axial scout images followed by multiple transverse slices (red arrows)
to include the whole lumbar enlargement (A, slice thickness = 1.0 mm, field of view = 1 cm × 1 cm). Diffusion-sensitizing gradients were applied in
six orientations: (Gx, Gy, Gz) = (1, 1, 0), (1, 0, 1), (0, 1, 1), (-1, 1, 0), (0, -1,1), and (1, 0, -1) with a gradient strength = 9 G/cm, duration (δ) = 7 ms, and
separation (Δ) = 18 ms, to obtain b values of 0 and 0.750 s/mm2. Regions of interest (ROIs) encompassing the ventrolateral white matter (VLWM)
was drawn manually on the DTI parameter maps (B). The boundary between white matter and gray matter was identified on relative anisotropy
(RA) maps. The clear gray-white matter contrast was seen in RA maps of all study groups. Radial (l⊥) and axial (l||) diffusivities showed
heterogeneous abnormalities within the VLWM, being more severe in saline- and vehicle-treated groups. Analysis of radial diffusivity and relative
anisotropy do not show differences between treatment groups, suggesting no differences in myelin integrity (C and E, One-way ANOVA F = 3.232,
P = 0.0227 and F = 5.272, P = 0.0021, respectively). Meanwhile, analysis of axial diffusivity shows a similarity between 10 mg/kg CCX771-treated
mice with naïve (D, One-way ANOVA, F = 3.232, P = 0.0227). Results are expressed as mean of l⊥, l|| or RA ± SD).
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23.0, P < 0.0001). These data strongly support a role for
CXCR7 as a disease-modifying molecule during the
recovery phase of EAE via axonal preservation.
CXCR7 antagonism does not alter myelin levels during
recovery from EAE
Prior studies evaluating the effect of CXCR7 antagonism
during EAE revealed decreased demyelination in mice
treated with CCX771 compared with vehicle-treated ani-
mals at the peak of disease [12]. Because we did not
observe any differences in measurements of radial diffu-
sivity between treatment groups after disease recovery,
we performed luxol fast blue (LFB) staining of spinal
cords at lumbar segments L2/3. Consistent with our
DTI data, there were no apparent differences between
any treatment groups in the VLWM myelin density as
detected by this method (Figure 5A). Of interest, mice
treated with 10 mg/kg CCX771 exhibited myelin-density
staining that was comparable to naïve animals (Figure
5A, upper panels). After 28 days post-adoptive transfer,
persistent inflammation was still detectable within the
VLWM spinal cords of saline- and vehicle-treated mice
and, to some extent, of mice treated with 5 mg/kg
CCX771, but not in mice treated with 10 mg/kg
CCX771 (Figure 5A, lower panels versus middle and
right upper panels). We also observed pathological fea-
tures consistent with hypertrophic and degenerating
axonal bundles, as reported in human and rodent mod-
els of CNS degeneration and trauma (Figure 5A, lower
panels, arrowhead) [33-39]. However, these features
were absent in the naïve and 10 mg/kg CCX771-treated
mice, where more normally appearing axons were pre-
sent (Figure 5A, mid-upper panel, arrow).
To better assess myelin protein expression and oligo-
dendrocyte numbers, we examined myelin basic protein
(MBP) and GST-π+ immunoreactivity. MBP expression
is frequently used for immunohistochemical analysis of
demyelination and remyelination in EAE [40-43] while
GST-π is a marker for mature oligodendrocytes [44-49].
Consistent with the LFB staining, MBP expression and
GST-π+ immunoreactivity within the VLWM was com-
parable among all treatment groups. Of note, MBP
staining exhibited more heterogeneity within the spinal
cords of mice with EAE that did not receive higher
Figure 3 Axial diffusivity threshold segmentation on VLWM of mouse spinal cord reveals similarities of CCX771-treated mice with
naïve. VLWM l|| distribution from naïve spinal cord (μ = 1.7, s = 0.36, n = 5) (A). Red line represents threshold of injured white matter from
naïve spinal cords used as control. The background image is the l|| maps (B). The red masks represent axial diffusivity threshold defined injured
axon (or white matter). Saline- and vehicle-treated mice showed extensive VLWM having abnormal axial diffusivity. Statistical analysis confirmed
no significant difference between naïve and 10 mg/kg CCX771-treated mice in contrast to the other groups (C, results are expressed as mean ±
SD. One-way ANOVA, F = 7.855, P = 0.0002).
Figure 4 Axial diffusivity defined abnormal VLWM volume correlates with clinical severity. Linear regression analysis of mean clinical
score during recovery phase as a function of axial diffusivity (A) and injured VLWM (B) (A, R2 = 0.5413, F = 33.04, DFn, DFd = 1.0, 28.0, P <
0.0001; B, R2 = 0.6520, F = 43.10, DFn, DFd = 1.0, 23.0, P < 0.0001). Area-under-curve (AUC) as a function of injured VLWM showed an R2 value of
0.7284 (C, F = 61.69, DFn, DFd = 1.0, 23.0, P < 0.0001).
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Figure 5 Myelin staining is consistent with DTI findings. Lumbar segments sections of 6 μm were stained with LFB and exhibited
comparable levels of myelination around ventral horns when observed at 5X of magnification (A scale bar = 50 μm). Persistent inflammation at
the meningeal surface was detected in 5 mg/kg CCX771-, vehicle- and saline-treated mice. At 40X magnification (offsets, scale bar = 20 μm) of
the same lumbar segment shown similar myelin distribution for 10 mg/kg CCX771-treated mice than naïve. At 40X magnification (offsets, scale
bar = 25 μm) normal axons could be identified (arrow) in mice treated with 10 mg/kg CCX771 while axonal bundles in different stages of
degeneration were observable to a lesser extent in 5 mg/kg CCX771-treated mice but, more abundant and severe in vehicle- and saline-treated
mice (arrowheads). Immunofluorescent detection of MBP (green) and GST-π (red) showed similar levels of myelin content and presence of
oligodendrocytes in all treatment groups (B scale bar = 25 μm). As observed with LFB, DAPI nuclear staining (blue) is more evident in the 5 mg/
kg CCX771-, vehicle- and saline-treated mice.
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doses of CXCR7 antagonist. These findings suggest that
CXCR7 antagonism preserves axons independent of
myelin recovery.
CXCR7 antagonism ameliorates persistent CNS
inflammation
To assess the phenotype of immune cells that persist
within the CNS parenchyma during recovery, spinal
cord tissues from our five treatment groups and naïve
controls were evaluated for meningeal and parenchymal
CD3+ cells in conjunction with GFAP expression, the
latter to delineate meningeal and parenchymal borders.
All treatment groups exhibited meningeal CD3+ cells,
which were increased in numbers in vehicle- and saline-
treated mice compared with mice treated with 5 mg/kg
or 10 mg/kg CCX771 (Figure 6A). Parenchymal infiltra-
tion of CD3+ cells was also increased in vehicle- and
saline-treated mice compared with mice treated with
CCX771, which exhibited few parenchymal CD3+ cells
(Figure 6A). Quantitative analysis of meningeal and par-
enchymal CD3+ staining within both the parenchyma
and meninges of mice in each treatment group revealed
significant differences between the two CNS regions in
mice treated with low dose CCX771 (5 mg/kg) and in
vehicle- or saline-treated controls but not in mice treated
with high dose CCX771 (10 mg/kg) (Figure 6B, Two-way
ANOVA interaction: F = 2.49, DFn = 5, DFd = 118, P =
0.0.347; antagonist treatment: F = 13.52, DFn = 5, DFd =
118, P < 0.0001; area of CNS (parenchyma or meninges):
F = 52.86 DFn = 1 DFd = 118, P < 0.0001). Comparison
of CD3 staining within the spinal cord parenchyma, but
not the meninges, across treatment groups revealed
highly significant differences between all treatment
groups and vehicle-treated controls (Table 3 One-way
ANOVA parenchyma: F = 10.56, p < 0.0001). These data
indicate that CXCR7 antagonism prevents persistent T
cell infiltration within the spinal cord parenchyma, which
could potentially contribute to ongoing axonal damage.
CXCR7 antagonism limits axonal injury during EAE
In order to assess the contents of spared spinal cord
VLWM in treatment groups after recovery from EAE,
spinal cords sections encompassing L2/3, which were the
same segments used for LFB staining, were examined for
the extent of neurofilament H (NF-H) dephosphorylation
via anti-SMI-32 immunofluorescence, as previously
reported [16,17,50,51]. SMI-32 immunopositivity was
found predominantly in neuronal cell bodies with little
detectable staining in the white matter in both groups of
10 mg/kg CCX771-treated mice and in naïve animals
(Figure 7A, upper panels). A similar pattern was observed
in the 5 mg/kg CCX771-treated mice group (Figure 6A,
left lower panel). Extensive SMI-32+ immunoreactivity,
however, was detected in the spinal cord VLWMs of
either saline- or vehicle-treated mice, even in areas where
myelin was present (Figure 5, middle and right lower
panels), consistent with DTI findings of axonal damage
(Figure 7A, middle and right lower panels). Further sta-
tistical analyses of SMI-32+ pixels/area within dorsal, lat-
eral and ventral spinal cord white matter of mice in each
treatment group revealed significant decreases between
CCX771-treated and naïve versus control animals only
within lateral and ventral regions (Figure 7B, 2-way
ANOVA interaction: F = 0.37, DFn = 10, DFd = 71, P =
0.9568; antagonist treatment: F = 3.25, DFn = 5, DFd =
71, P = 0.0107; white matter area: F = 1.46 DFn = 2, DFd
= 71, P = 0.2388). These data support the DTI findings
and that CXCR7 antagonism in the setting of EAE pre-
vents axonal damage in a dose dependent fashion.
Conclusions
The current study utilized in vivo DTI to evaluate the
role of CXCR7 in recovery from EAE and provides com-
pelling evidence that CXCR7 antagonism prevents
inflammatory-mediated injury to axons. Axial diffusivity
measurements of injured spinal cord VLWM in mice
treated with CXCR7 antagonist were undistinguishable
from those of naïve mice, which were both significantly
different from vehicle- and saline-treated mice. Consis-
tent with this, extensive SMI-32+ immunoreactivity
within spinal cord VLWM was detected in both saline-
or vehicle-treated mice but not in tissues obtained from
mice treated with CXCR7 antagonist. In contrast, there
were no differences in radial diffusivity measurements or
extent of LFB staining, MBP+ and GST-π+ immunoreac-
tivity between groups, suggesting that axonal preserva-
tion in the setting of CXCR7 antagonism may be
independent of myelin repair. A linear correlation
between injured VLWM and mean maximal disease
severity scores was observed only during recovery phase,
consistent with the notion that immune-mediated axonal
damage persists at late stages of EAE in control-treated
animals. Consistent with this, we observed significant
increases in persistent inflammatory infiltrates within the
parenchyma of saline- and vehicle-treated mice that was
abrogated with CCX771 administration. These control
tissues also exhibited the presence of pathological fea-
tures consistent with hypertrophic-degenerative axonal
bundles [33-39], suggesting that axonal damage and not
lack of myelin is the key pathology in mice with chronic
deficits. These findings support the relevance of CXCR7
antagonist treatment to preserve axonal integrity and
indicate that DTI may be used to determine the treat-
ment effects of small molecule inhibitors on pathological
biomarkers of CNS autoimmunity.
A growing body of evidence supports the notion that
neurologic dysfunction in MS occurs as a result of axonal
degeneration [1], which may be dependent on or occur
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Figure 6 Injured VLWM shows evidence of persistent inflammation. Double immunofluorescence analysis of infiltrated CD3+ T-cells (green)
using GFAP (red) antibody to delineate CNS parenchyma within spinal cords of mice evaluated by DTI (A). T cells were absent on spinal cords
from naïve mice while some CD3+ lymphocytes were detected on CCX771-treated mice. However, these CD3+ T-cells were mostly restricted to
meningeal spaces and within GFAP+ parenchyma. Vehicle- and saline-treated mice showed a higher infiltration of CD3+ lymphocytes within
GFAP+ parenchyma. As observed with LFB, To-Pro-3 nuclear staining (blue) is more evident in the 5 mg/kg CCX771-, vehicle- and saline-treated
mice. (A 63X magnification, scale bar = 25 μm). Statistical analysis shows significant differences in CD3+ pixel ratios within ROI’s (parenchyma
and meninges) among treatment groups (B results are expressed as mean CD3+ pixels per ROI ± SEM. Two-way ANOVA P values summary:
interaction F = 2.49, P = 0.0347; antagonist treatment F = 13.52, P < 0.0001; area of CNS (parenchyma or meninges) F = 52.86, P < 0.0001).
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independently of chronic demyelination [52]. Demyelina-
tion-dependent mechanisms include ongoing axonal
toxicity due to the up-regulation of sodium channels
throughout the length of demyelinated axons in MS and
EAE. Consistent with this, mice deficient in Na+ channel
beta2 subunits exhibit decreased axonal degeneration
and loss during EAE compared with wild-type animals,
despite similar levels of CNS inflammation [53]. How-
ever, myelinated axonal segments continuously exposed
to activated macrophages or their products can undergo
focal degeneration with associated mitochondrial
Table 3 One-way ANOVA comparing CD3+ pixels ratio
within parenchyma.
10 mg vehicle to 10 mg 5 mg vehicle saline
10 mg – ns ns *** **
vehicle to 10 mg ns – ns ** ns
5 mg ns ns – *** ns
vehicle *** ** *** – ns
saline ** ns ns ns –
Summary of p values comparing the ratio of CD3+ pixels within parenchyma
from each treatment group. ns = non-significant, * = p < 0.05, ** p < 0.01, ***
p < 0.001, P < 0.0001, F = 10.56, R2 = 0.4599.
Figure 7 Injured VLWM shows abnormal dephosphorylation of Neurofilament H. Immunofluorescence analysis of NF-H was assessed using
SMI-32 antibody immunoreactivity to detect dephosphorylation within spinal cords after DTI evaluation (A). Higher SMI-32 staining within VLWM
was observed in saline- and vehicle-treated mice in contrast to naïve controls, while CCX771-treated mice were more comparable to control
mice (63X magnification, scale bar = 25 μm). Statistical analysis shows significant differences within lateral and ventral portions of the spinal cord
white matter area (B results are expressed as mean SMI-32+ pixels per area ± SEM. Two-way ANOVA P values summary: interaction F = 0.3671, P
= 0.9568; antagonist treatment F = 3.248, P = 0.0107; area F = 1.4661, P = 0.2382.).
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dysfunction [8], suggesting that inflammatory mediators
may induce axonal damage without demyelination [8].
Consistent with this, using the Biozzi ABH murine
model, Jackson and colleagues demonstrated that axonal
pathology is the primary event in relapsing-progressive
EAE [54]. These investigators observed axonal loss in the
acute phase of disease prior to demyelination with further
axonal loss in the absence of chronic inflammation dur-
ing relapses. In our study, vehicle-treated mice with
ongoing disease could attain complete recovery upon
initiation of CXCR7 antagonist, suggesting peak disease
contains a reversible component. Because all groups
exhibited equal levels of radial but not axial diffusivity,
this reversibility may be attributed to axonal damage. In
our previous work, we demonstrated that CXCR7 antag-
onism decreased infiltration of immune cells to CNS
parenchyma as assessed by both, immunohistochemistry
and flow cytometry [12]. Thus, T cell entry is likely to be
a primary event that reversibly injures axons. Consistent
with this, CD8+ T cells reportedly cause bystander axonal
damage in murine cerebellar slice cultures [55]. Another
putative mechanism is T cell-mediated axonal dysfunc-
tion via microtubule destabilization, which was observed
to cause synaptic impairment and accumulation
of APP aggregates [56,57]. Further studies utilizing
CXCR7 antagonist are ongoing to address these possible
mechanisms.
Recent studies indicate that oligodendrocyte precursor
cells (OPCs) express both CXCL12 receptors and that
CXCL12 is essential for remyelination [58-62]. Thus, it is
possible that CXCR7 antagonism impacts on OPC biology.
Although EAE-recovered vehicle- versus CXCR7 antago-
nist-treated mice exhibit equivalent levels of myelin, as
assessed by DTI, LFB staining, MBP and GST-π immuno-
histochemal analyses, detection of new myelin may be bet-
ter accomplished using non-immune-mediated models of
demyelination, such as cuprizone toxicity. Mice fed the
copper chelator cuprizone display specific demyelination
of the corpus callosum, which exhibits remyelination upon
cessation of toxin [59]. Studies examining CXCR7 antag-
onism in this context may be more conducive for the
evaluation of OPCs recruitment and maturation. Alterna-
tively, as CXCR7 antagonism was previously shown to
limit demyelination during peak EAE [12], it is possible
that the preserved axonal integrity is due to preservation
of myelin.
Prior studies have revealed a strong correlation
between changes in axial diffusivity and white matter
pathology via quantitative pixelwise DTI analysis [17],
strengthening the usefulness of axial diffusivity as a bio-
marker for axonal integrity. Nevertheless, while several
studies have demonstrated efficacy for DTI in evaluating
in vivo treatment modalities in animal models of CNS
injury [63,64], this is the first study evaluating a
pharmacological inhibitor in a murine model of MS in
vivo. Mi et al., showed that treatment of Sprague-Dawley
rats with anti-LINGO-1 promotes recovery from MOG-
induced EAE, either by intrathecal or systemic delivery
[65]. These investigators also correlated EAE ameliora-
tion with axonal integrity as assessed by axial diffusivity;
however, imaging was performed post-mortem in fixed
spinal cord specimens. More recently, DTI has been
used successfully in patients for the evaluation of G-CSF
treatment for amyotrophic lateral sclerosis [66] and
anti-tubercular treatment for Tuberculous meningitis
[67], highlighting the feasibility of DTI for evaluating
CNS lesions and inflammation.
In summary, our study provides evidence that CXCR7
antagonism in the setting of CNS autoimmunity pre-
vents axonal loss, as assessed by both novel imaging and
standard histological modalities. In addition, our work
supports the use of DTI, especially axial diffusivity, as a
non-invasive biomarker for the detection of axonal
integrity in EAE and MS.
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